查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1986854

止血和组织密封剂市场规模、份额、趋势和预测：按产品类型、材料类型、应用、最终用户和地区划分，2026-2034年

Hemostasis and Tissue Sealing Agents Market Size, Share, Trends and Forecast by Product Type, Material Type, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2025年全球止血和组织密封市场规模为76.8亿美元。展望未来，IMARC集团预测，该市场将以5.65%的复合年增长率从2026年增长至2034年，到2034年达到126.1亿美元。目前，北美市场主导地位，预计2025年将占40%的市场。该地区受益于完善的医疗基础设施、先进的外科技术、止血产品的广泛应用、有利的报销政策以及慢性病患病率上升带来的大量手术，所有这些因素都促进了止血和组织密封市场份额的增长。

全球外科手术数量的不断增长是止血剂和组织封闭剂需求的主要驱动因素。在心血管外科、整形外科和一般外科手术中，采用有效的止血管理和组织封闭技术对于改善患者预后、预防术后併发症和出血变得日益重要。糖尿病、癌症和心血管疾病等慢性病的日益普遍也促使需要使用这些专用产品的外科手术需求增加。同时，微创手术的日益普及也影响止血剂和组织封闭剂的需求。此外，老年人口的成长（老年人更容易患慢性病和出现手术併发症）也推动了止血剂和组织封闭剂市场的成长。

美国已成为止血和组织缝合产品的重要市场。美国拥有完善的医疗保健体系，民众对医疗研发投入庞大，医生也使用最先进的手术器材。随着心臟病、糖尿病和癌症发生率的不断上升，手术变得越来越必要。医生需要能够止血并紧密缝合组织。根据CRT集团基金会2022年8月发布的消息，预计2025年至2060年间，美国高血压患者人数将增加27.2%，从1.278亿增至1.625亿。 2025年，美国心臟协会（AHA）和美国心臟学会（ACC）将「健康」血压的目标值设定为130/80 mmHg或更低。此外，由于美国的保险制度补贴了复杂疾病的治疗费用、人口老化以及对微创手术的需求不断增长，美国的止血剂和组织密封剂市场正在迅速增长。

止血剂和组织密封剂市场趋势

微创手术的需求正在激增。

随着医生采用尽可能减少体内切口的手术方法，外科技术正在迅速发展。这改变了医生止血和修復组织的需求。当医生使用医疗设备透过极小的切口进行手术时，就需要能够在狭小空间内使用的专用辅助器具。这些新的手术方法对患者有益，因为它们可以减轻术后疼痛并缩短住院时间。这些手术方法为患者提供了显着的优势，例如更短的恢復时间，这促使它们被临床医生和患者广泛接受。随着对这些技术的支援不断增长，製造商被迫开发适用于微创手术的先进止血产品。此外，手术器械、高清成像和机器人系统的不断改进，进一步扩大了微创手术在多个专科领域的应用范围，从而持续满足对有效止血解决方案的需求。 2025年，一家都市区医院引进了一种治疗痔疮的新型微创技术。这使得患者能够避免与创伤性更大的手术相关的不适，并更快地恢復日常生活。 「拉斐尔疗法」是在波兰开发的，采用射频消融术在局部麻醉下治疗痔疮，目前在阿波罗光谱医院进行。

产品配方方面的技术进步

止血和组织密封剂的技术创新显着提升了产品的功效、安全性和易用性，从而提振了止血和组织密封剂的市场前景。这些新技术包括生物材料的製造、改进的输送系统以及增强的止血功能，这些功能能够促进血液凝固和伤口护理。可生物降解和生物相容性製剂会分解，有助于消除人们对其与人体相容性和使用安全性的担忧。这意味着这些材料会在6到8週内逐渐从体内排放，而无需取出。例如，2025年4月，百特国际在欧洲推出了HemoPatch，这是一种可在室温下储存的止血和组织密封剂。这无需冷藏，保存期限长达3年。这些创新将提高手术效率，最大限度地减少产品浪费，并改善开放式手术和微创手术的整体止血效果。

全球慢性病盛行率不断上升

心血管疾病、癌症和糖尿病等慢性疾病的日益流行是止血剂和组织封闭剂需求的主要驱动因素，从而推动了止血剂和组织封闭剂市场的发展。由于慢性疾病的诊断、治疗或管理通常需要手术干预，因此对高效止血剂和组织封闭剂的需求始终存在。糖尿病足溃疡、压疮和静脉溃疡等慢性伤口是常见的併发症，通常需要手术清创、伤口缝合或处理，因此这些药物对于确保止血和促进治疗至关重要。此外，慢性病患者通常伴随其他疾病，这会增加手术过程中出血併发症的风险。例如，根据慢性病伙伴关係（PFCD）发布的最新国家和州级统计数据，2024年至2039年间，慢性病可能对美国造成高达47兆美元的损失，导致每年医疗保健支出2.2兆美元，到2039年每年生产力损失约9,000亿美元。由生活方式改变、环境因素和人口老化等因素导致的全球疾病负担日益加重，持续为止血剂创造了庞大的市场。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球止血与组织密封剂市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依产品类型划分

  • 局部止血剂
  • 黏合剂和组织密封剂

第七章 市场区隔：依材料类型划分

  • 胶原蛋白蛋白
  • 氧化再生纤维素（ORC）
  • 明胶基
  • 多醣
  • 其他的

第八章 市场区隔：依应用领域划分

  • 一般外科
  • 微创手术
  • 其他的

第九章 市场区隔：依最终用户划分

  • 医院
  • 门诊手术中心
  • 居家照护设施
  • 其他的

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Advanced Medical Solutions Group plc
    • Artivion, Inc
    • B. Braun SE
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • BioCer Entwicklungs-GmbH
    • Ethicon, Inc.（Johnson & Johnson）
    • Medtronic
    • Pfizer Inc.
    • Terumo Aortic
Product Code: SR112026A6397

The global hemostasis and tissue sealing agents market size was valued at USD 7.68 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.61 Billion by 2034, exhibiting a CAGR of 5.65% from 2026-2034. North America currently dominates the market, holding a market share of 40% in 2025. The region benefits from well-established healthcare infrastructure, widespread adoption of advanced surgical technologies and hemostatic products, favorable reimbursement policies, and a high volume of surgical procedures driven by the rising prevalence of chronic diseases, all contributing to the hemostasis and tissue sealing agents market share.

The increasing number of surgical procedures being performed across the globe is one of the key drivers that are fueling the demand for hemostasis and tissue sealing agents. Cardiovascular, orthopedic, and general surgeries are increasingly adopting the use of effective hemostatic control and tissue sealing to ensure better patient outcomes and to prevent post-operative complications and blood loss. The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is also contributing to the growing demand for surgical procedures that require the use of these specialized products. At the same time, the increasing adoption of minimally invasive surgical procedures is also influencing the demand for hemostats and tissue sealing agents. Additionally, the expanding geriatric population, which is more susceptible to chronic ailments and surgical complications, is supporting the hemostatic and tissue sealing agents market growth.

The United States has become a place for the market of things that help stop bleeding and seal tissues. The United States has a good healthcare system people are putting a lot of money into medical research and new developments and doctors are using the latest surgical tools. More people are getting sick with things like heart problems, diabetes and cancer so they need to have surgery. The doctors need to be able to stop the bleeding and seal the tissues well. As per information released by the CRT Group Foundation in August 2022, the count of people experiencing hypertension in the United States is expected to rise by 27.2%, reaching 162.5 million from 127.8 million between 2025 and 2060. In 2025, the American Heart Association (AHA) and the American College of Cardiology (ACC) established a specific goal for "healthy" blood pressure, below 130/80 mm Hg. Also, the United States has insurance plans that help pay for complicated illnesses, the population is getting older and more people want to have surgery that is not too invasive so the market for hemostasis and tissue sealing agents in the United States is growing rapidly.

HEMOSTASIS AND TISSUE SEALING AGENTS MARKET TRENDS:

Surging Demand for Minimally Invasive Surgeries

The way doctors do surgery is changing fast because they are using methods that do not cut the body as much. This is changing what doctors need to stop bleeding and fix tissues. When doctors do surgery with machines and tiny cuts they need special helpers that can be used in small spaces. These new ways of doing surgery are beneficial for patients because they hurt less after the surgery they can go home from the hospital sooner. These procedures offer significant patient benefits, including faster recovery times, which have driven their widespread acceptance among both clinicians and patients. The growing preference for these techniques is compelling manufacturers to develop advanced hemostatic products with superior applicability in minimally invasive settings. Moreover, continuous improvements in surgical instrumentation, high-definition imaging, and robotic systems are further expanding the scope of minimally invasive procedures across multiple specialties, sustaining demand for effective hemostatic solutions. In 2025, a novel, minimally invasive technique for addressing haemorrhoids, permitting patients to evade the discomfort of extensive surgery and quickly return to their usual routines, was introduced at a city hospital. The Rafaelo procedure, which involves radiofrequency ablation of hemorrhoids with local anesthesia, was developed in Poland and is being performed at Apollo Spectra.

Technological Advancements in Product Formulations

Technological innovations in hemostasis and tissue sealing agents are significantly enhancing product efficacy, safety, and ease of use, thereby propelling the hemostasis and tissue sealing agents market outlook. These new developments include the production of biomaterials, better delivery systems, and enhanced hemostatic aspects making sure they help blood clot and wounds heal better. Biodegradable and biocompatible agents can be broken down which helps with concerns about how well they work with the body and if they are safe to use. This means the body can slowly get rid of these materials over six to eight weeks without needing to take them out. For instance, in April 2025, Baxter International introduced the Hemopatch sealing hemostat with room-temperature storage in Europe, eliminating the need for refrigeration and offering a three-year shelf life. These innovations enhance surgical efficiency, minimize product wastage, and improve overall hemostatic performance during both open and minimally invasive procedures.

Rising Prevalence of Chronic Diseases Worldwide

The rising incidence of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is a major driver fueling the demand for hemostasis and tissue sealing agents, thus contributing to the hemostasis and tissue sealing agents market forecast. Chronic diseases often require surgical procedures for diagnosis, treatment, or management, thus ensuring a constant demand for efficient hemostatic and tissue sealing agents. Chronic wounds such as diabetic foot, pressure sores, and venous ulcers are frequent complications that often require surgical debridement, closure, or management, where these agents are crucial in ensuring hemostasis and facilitating faster healing. Furthermore, patients with chronic diseases often have comorbid conditions that raise the risk of surgical bleeding complications. For example, new national and state statistics released by the Partnership to Fight Chronic Disease (PFCD) indicate that chronic disease could result in costs of up to $47 trillion for the United States from 2024 to 2039, contributing $2.2 trillion annually in medical expenses and nearly $900 billion annually in lost productivity by 2039. The rising burden of diseases worldwide, driven by lifestyle changes, environmental conditions, and the growing elderly population, continues to create a vast market for hemostatic agents.

HEMOSTASIS AND TISSUE SEALING AGENTS INDUSTRY SEGMENTATION:

Analysis by Product Type:

  • Topical Hemostats
  • Adhesive and Tissue Sealant

Adhesive and tissue sealant holds 54% of the market share. Adhesive and tissue sealant products encompass solutions designed to seal tissues, close wounds, or bond tissues together during surgical procedures. Available in liquid, gel, or film forms, these products are applied directly to the tissue surface, creating a biocompatible barrier that promotes wound healing and prevents leakage or further bleeding. The segment benefits from increasing preference for products that offer faster wound closure, reduced operating times, and lower post-operative infection risks compared to traditional suturing methods. The growing adoption of minimally invasive surgical procedures, where precise tissue sealing through small incisions is essential, is further amplifying demand for advanced sealant solutions. For instance, in November 2023, Ethicon, a part of Johnson and Johnson, gained European approval for its ETHIZIA hemostatic sealing patch, which provides effective results on both sides of the wound and stops bleeding in 30 seconds for 80% of patients.

Analysis by Material Type:

  • Collagen-based
  • Oxidized Regenerated Cellulose (ORC) based
  • Gelatin-based
  • Polysaccharide-based
  • Others

Gelatin-based leads the market with a share of 33%. Gelatin-based hemostats are derived from collagen obtained from animal sources, predominantly bovine or porcine, and possess intrinsic hemostatic properties that are often enhanced through combination with thrombin or other clotting factors. These hemostats are available in various forms, including sponges, powders, and sheets, offering versatility across diverse surgical applications. The segment benefits from the material's proven biocompatibility, cost-effectiveness, and ability to promote both platelet aggregation and wound healing simultaneously. Gelatin-based products are widely used across cardiovascular, orthopedic, and general surgical procedures to control bleeding and facilitate tissue repair. For instance, in 2025, GELITA, a producer of collagen and gelatin, has revealed the introduction of its Endotoxin Controlled Excipients (ECE) range. This product range, including VACCIPRO and MEDELLAPRO, satisfies the rigorous requirements of contemporary biomedical and pharmaceutical uses, such as vaccine stabilization, medical equipment, and 3D bioprinting. The growing demand for reliable and affordable hemostatic solutions in both developed and emerging healthcare systems continues to reinforce the segment's leading position.

Analysis by Application:

  • General Surgery
  • Minimally Invasive Surgery
  • Others

General surgery dominates the market, with a share of 36%. General surgery encompasses a broad spectrum of surgical procedures involving various organs and tissues within the body, including appendectomies, hernia repairs, gallbladder removals, and bowel surgeries. Hemostasis and tissue sealing agents play a crucial role in these procedures by controlling bleeding from incisions, dissected tissues, and damaged vessels, thereby ensuring optimal surgical outcomes and patient recovery. The segment's dominance is underpinned by the sheer volume of general surgical procedures performed annually across healthcare systems worldwide. As surgical complexity increases and patients present with more comorbidities, the need for effective hemostatic control during general surgical interventions continues to expand. For instance, according to the International Journal of Surgery, approximately 310 million major surgeries are carried out annually worldwide, with 40 to 50 million taking place in the United States. The growing emphasis on reducing post-operative complications and improving patient outcomes further supports the segment's leading market position.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

Hospitals represent the leading segment, with a market share of 56%. Hospitals serve as the primary settings for a wide range of medical interventions, including complex surgical procedures that require effective hemostasis and tissue sealing agents. These facilities encompass specialized departments such as operating rooms, emergency departments, and intensive care units where surgeries of varying complexity are performed. The segment's dominance is attributable to the comprehensive resources available within hospital settings, including advanced surgical equipment, trained healthcare personnel, and integrated diagnostic and therapeutic services. Hospitals handle the highest volume of surgical procedures, particularly for chronic disease management, trauma care, and emergency interventions, all of which demand reliable hemostatic products. For instance, according to data published, hospitals held a major percentage share of the hemostasis products market in 2025, reflecting their pivotal role in driving demand. The ongoing expansion of hospital infrastructure globally further reinforces the segment's leading market position in the hemostasis and tissue sealing agents market trends.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 40% of the share, enjoys the leading position in the market. The region's dominance is primarily driven by well-established healthcare infrastructure, high adoption rates of innovative surgical technologies, and the presence of major market players who continuously invest in research and development. North America benefits from a high volume of surgical procedures, particularly for chronic diseases such as cardiovascular disorders, diabetes, and cancer, which create sustained demand for effective hemostatic and tissue sealing products. Favorable reimbursement policies and stringent regulatory standards further support market growth in the region. For instance, the United States minimally invasive surgery market was valued at USD 25.7 Billion in 2024 and is projected to reach USD 36.3 Billion by 2033, growing at a CAGR of 3.73% during 2025-2033, reflecting the strong demand for surgical products including hemostatic agents. Additionally, the well-established network of hospitals and ambulatory surgical centers ensures widespread availability and utilization of these products.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

The United States represents the largest national market for hemostasis and tissue sealing agents, driven by the country's extensive healthcare infrastructure, high surgical volumes, and widespread adoption of advanced medical technologies. The rising prevalence of chronic conditions, including cardiovascular diseases, diabetes, and cancer, continues to generate substantial demand for surgical interventions requiring effective hemostatic control. The country's aging population is particularly susceptible to conditions necessitating surgical procedures, further sustaining market demand. Additionally, the United States benefits from strong reimbursement frameworks that support the adoption of advanced hemostatic products across hospitals and ambulatory surgical centers. The growing preference for minimally invasive surgical techniques, including robotic-assisted procedures, is driving demand for hemostats and sealants specifically designed for use through small incisions. A survey commissioned by the Society of Interventional Radiology (SIR) and carried out by The Harris Poll uncovered notable insights regarding the treatment choices available to women diagnosed with uterine fibroids. The survey, involving more than 1,000 women in the USA, revealed that a considerable majority of women diagnosed with uterine fibroids were mainly offered hysterectomy as a treatment option (53%). Conversely, under 20% had knowledge of less invasive options like over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs), uterine fibroid embolization (UFE), oral contraceptives, and endometrial ablation.

EUROPE HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Europe represents a significant market for hemostasis and tissue sealing agents, supported by a well-developed healthcare system, strong regulatory frameworks, and favorable government-backed reimbursement policies that encourage the adoption of innovative surgical products. The region benefits from high adoption rates of advanced hemostatic solutions across cardiovascular, orthopedic, and general surgical procedures. Key markets including Germany, France, and the United Kingdom drive regional demand through their established hospital networks and ongoing investments in surgical technology. The implementation of the Medical Device Regulation has strengthened product quality standards, promoting the use of clinically validated hemostatic agents. For instance, in April 2025, Baxter International launched the Hemopatch sealing hemostat with room-temperature storage across European markets, eliminating refrigeration requirements and offering enhanced accessibility for surgical teams. Moreover, the growing geriatric population in Europe, coupled with increasing surgical volumes and rising prevalence of chronic diseases, continues to expand the addressable market for hemostatic and tissue sealing products across the region.

ASIA-PACIFIC HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Asia-Pacific is emerging as the fastest-growing regional market for hemostasis and tissue sealing agents, driven by rapid healthcare infrastructure expansion, rising surgical volumes, and increasing government investments in healthcare across major economies. Countries including China, Japan, India, South Korea, and Australia are witnessing significant improvements in medical facility capabilities, enabling greater adoption of advanced surgical technologies and hemostatic products. The rising prevalence of chronic diseases, expanding medical tourism, and growing awareness of advanced surgical techniques are further catalyzing regional market growth. For instance, in India, nearly 100 out of every 1 lakh people are diagnosed with cancer, underscoring the vast patient population requiring surgical intervention and hemostatic management. Additionally, favorable government policies aimed at improving healthcare access and increasing per capita healthcare expenditure continue to support market expansion across the region.

LATIN AMERICA HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

Latin America presents growing opportunities for hemostasis and tissue sealing agents, supported by improving healthcare infrastructure, rising surgical volumes, and increasing economic development across the region. Brazil, Mexico, and Argentina represent key markets where expanding hospital networks and growing access to advanced surgical technologies are driving demand for hemostatic products. The increasing emphasis on modernizing healthcare systems and improving access to essential surgical services is creating new opportunities for market growth. For instance, the Brazilian government has allocated substantial funding toward expanding public healthcare infrastructure, supporting the growth of surgical services. The growing prevalence of chronic diseases and rising awareness of advanced surgical techniques further support market growth.

MIDDLE EAST AND AFRICA HEMOSTASIS AND TISSUE SEALING AGENTS MARKET ANALYSIS

The Middle East and Africa region offers emerging growth potential for hemostasis and tissue sealing agents, driven by ongoing healthcare infrastructure development, increasing government investments in medical facilities, and growing surgical volumes. The region is witnessing rising demand for advanced hemostatic products as healthcare systems expand to address the growing burden of chronic diseases and trauma cases. Moreover, governments are launching public robotic surgery facility, reflecting the broader trend of expanding advanced surgical capabilities across emerging markets. Improving healthcare access and increasing awareness of modern surgical techniques continue to support market development.

COMPETITIVE LANDSCAPE:

The hemostasis and tissue sealing agents market features a moderately consolidated competitive landscape, with several established multinational corporations holding significant market positions through extensive product portfolios, robust distribution networks, and continuous investments in research and development. Key players are actively pursuing strategies including product innovation, strategic acquisitions, geographic expansion, and collaborative partnerships to strengthen their competitive positioning. The market has witnessed notable merger and acquisition activity, with companies seeking to broaden their product offerings and enhance technological capabilities in hemostatic solutions. Additionally, companies are increasingly focusing on developing next-generation hemostatic agents with improved biocompatibility, faster clotting mechanisms, and enhanced storage stability to address evolving surgical requirements across diverse clinical settings worldwide.

The report provides a comprehensive analysis of the competitive landscape in the hemostasis and tissue sealing agents market with detailed profiles of all major companies, including:

  • Advanced Medical Solutions Group plc
  • Artivion, Inc
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BioCer Entwicklungs-GmbH
  • Ethicon, Inc. (Johnson & Johnson)
  • Medtronic
  • Pfizer Inc.
  • Terumo Aortic

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the hemostasis and tissue sealing agents market?

2. What is the future outlook of the hemostasis and tissue sealing agents market?

3. What are the key factors driving the hemostasis and tissue sealing agents market?

4. Which region accounts for the largest hemostasis and tissue sealing agents market share?

5. Which are the leading companies in the global hemostasis and tissue sealing agents market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemostasis and Tissue Sealing Agents Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Topical Hemostats
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adhesive and Tissue Sealant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Material Type

  • 7.1 Collagen-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxidized Regenerated Cellulose (ORC) based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Gelatin-based
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Polysaccharide-based
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 General Surgery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Minimally Invasive Surgery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Care Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Advanced Medical Solutions Group plc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Artivion, Inc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 B. Braun SE
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Baxter International Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Becton, Dickinson and Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 BioCer Entwicklungs-GmbH
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Ethicon, Inc. (Johnson & Johnson)
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Medtronic
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Terumo Aortic
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemostasis and Tissue Sealing Agents Market: Major Drivers and Challenges
  • Figure 2: Global: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Material Type (in %), 2025
  • Figure 6: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Hemostasis and Tissue Sealing Agents Industry: SWOT Analysis
  • Figure 87: Global: Hemostasis and Tissue Sealing Agents Industry: Value Chain Analysis
  • Figure 88: Global: Hemostasis and Tissue Sealing Agents Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemostasis and Tissue Sealing Agents Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Material Type (in Million USD), 2026-2034
  • Table 4: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Hemostasis and Tissue Sealing Agents Market: Competitive Structure
  • Table 8: Global: Hemostasis and Tissue Sealing Agents Market: Key Players